Skip to content
Open access

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways

Aug 2026 · Journal of Pathology · Vol 270, pp. 380 - 395 · 0 citations · 74 references
Medicine

TL;DR

It is proposed that MEK inhibitors may represent a relevant therapeutic option for BRAF fusions and non‐V600 BRAF mutant tumours, providing a novel strategy for this challenging disease.

Abstract

Mucosal melanomas (MMs) are rare, aggressive cancers with poor outcomes and limited response to standard therapies. A significant knowledge gap exists regarding their genomic landscape and corresponding druggable targets. This study explores this issue through a multi‐omic analysis, including whole exome‐, RNA‐, and targeted sequencing, of unique sinonasal mucosal melanoma (SN‐MM) cell lines. SN‐MM cell lines showed a low tumour mutational burden and low genomic instability, suggesting that their DNA repair mechanisms are largely intact. However, they exhibited a high prevalence of structural variants, likely from catastrophic genomic events. We also found novel, clinically actionable variants, including oncogenic fusion transcripts. Key findings, such as fusion transcripts and single‐nucleotide variants, were validated on diagnostic biopsies. Moreover, using a break‐apart FISH assay, we identified BRAF rearrangements as recurrent events in MM, supporting their biological relevance. The MAPK pathway was found to have a significant functional role, sustained by variants such as BRAF p.Asn581Ser, NRAS p.Gly12Asp, and the MKRN1::BRAF fusion. This pathway activation was effectively inhibited by the MEK inhibitor trametinib. This genomic and functional profiling unveiled novel molecular hubs in MM. The findings propose that MEK inhibitors may represent a relevant therapeutic option for BRAF fusions and non‐V600 BRAF mutant tumours, providing a novel strategy for this challenging disease. Further molecular and functional validation of novel variants, and particularly of BRAF rearrangements, may reveal additional clinically relevant therapeutic targets. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Read PDF

Similar papers

Open access Sep 2026

Integrative Multi‐Omics Profiling Reveals Age‐Associated Genomic and Tumor Microenvironmental Heterogeneity in Colorectal Cancer

Early‐onset colorectal cancer (EOCRC) is increasing worldwide, yet the molecular basis underlying its age‐related heterogeneity remains insufficiently defined. To address this gap, we performed whole‐exome sequencing in a Chinese EOCRC cohort diagnosed before 40 years of age ( n  = 111), bulk transcriptome sequen...

Yang Guo, Ya-Jiao He, Tao Zhou et al. · 0 citations
Review Open access Sep 2026

Genomic landscape of sweat gland carcinomas: Clinical applications and future directions.

This review provides a comprehensive overview of SGC entities and summarizes current knowledge of their mutational landscapes to improve understanding of their biology and identify potential therapeutic targets, particularly for aggressive tumors lacking treatment options in advanced stages.

Lara Racz, A. Böer-Auer, F. Meier et al. · 0 citations
Open access Oct 2026

Integrated multi-omics analysis reveals the molecular landscape and therapeutic strategies in Chinese cervical cancer patients

Genomic or transcriptomic sequencing guides the precision of cervical cancer (CC) diagnosis; however, the molecular profile of Asian patients remains poorly understood. We established a comprehensive multi-omics cohort comprising 112 tumor-normal adjacent tissue pairs from Chinese CC patients. Our integrated analysis r...

Tao Pan, Xu-Cui Zhuang, Ya Zhang et al. · 0 citations
Open access Sep 2026

Clustered structural variant hotspots enable oncogenic addiction and plasticity in osteosarcoma

Across 236 whole-genome sequencing osteosarcoma samples, five genomic hotspots of clustered structural variation collectively altered in 58% of tumors were uncovered, and localized transcriptional dysregulation at hotspot event loci was found, linking these structural alterations to a less differentiated cell state.

Shreya Raman, Thorsten Kaltenbacher, David Merrell et al. · 0 citations
Review Aug 2026

Integrated molecular, epigenetic, microbial and liquid biopsy biomarkers in colorectal cancer: implications for prognosis and precision therapy

Abstract Background Colorectal cancer (CRC) is a biologically diverse malignancy driven by a complex interplay of genetic mutations, epigenetic changes, tumour microenvironmental factors and host–microbial interactions. Foundational molecular events including APC-associated Wnt/β-catenin dysregulation, TP53 inactivatio...

Suvarna Bhokare, A. Wagh, P. Jadhav et al. · 0 citations
Open access Aug 2026

Genomic and Transcriptomic Profiling of Testicular Germ Cell Tumors: Identifying Key Driver Mutations and Structural Variants via the cBioPortal Platform

The distinct association of KRAS and KIT with the seminomatous lineage, alongside the broad histological distribution of PTMA, provides novel insights into tumor biology, and may contribute to improved diagnostic precision and the development of tailored therapeutic interventions for patients with TGCT.

B. Calim-Gurbuz · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.